WIPO logo
Mobile | Deutsch | English | Español | Français | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

国際・国内特許データベース検索
World Intellectual Property Organization
検索
 
閲覧
 
翻訳
 
オプション
 
最新情報
 
ログイン
 
ヘルプ
 
自動翻訳
1. (WO2017200183) PHARMACEUTICAL COMPOSITION USING LACTOBACILLUS SP. KCCM 11826P STRAIN FOR PREVENTING HYPERPHOSPHATEMIA AND FOR TREATING CHRONIC KIDNEY DISEASE AND HEALTH FUNCTIONAL FOOD
国際事務局に記録されている最新の書誌情報    第三者情報を提供

国際公開番号: WO/2017/200183 国際出願番号: PCT/KR2017/000997
国際公開日: 23.11.2017 国際出願日: 26.01.2017
IPC:
A23L 33/135 (2016.01) ,A61K 35/747 ,C12R 1/225 (2006.01)
出願人: KOREA FOOD RESEARCH INSTITUTE[KR/KR]; 62, Anyangpangyo-ro 1201beon-gil, Bundang-gu Seongnam-si Gyeonggi-do 13539, KR
CATHOLIC KWANDONG UNIVERSITY INDUSTRY FOUNDATION[KR/KR]; 24, Beomil-ro 579beon-gil Gangneung-si Gangwon-do 25601, KR
発明者: KIM, Hyo Jin; KR
JANG, Hae Won; KR
CHIN, Young-Wook; KR
KANG, Woo Kyung; KR
MOON, Sung Jin; KR
代理人: TAEDONG INTERNATIONAL PATENT&LAW FIRM; 302, 282, Gamasan-ro Guro-gu Seoul 08302, KR
優先権情報:
10-2016-005992517.05.2016KR
発明の名称: (EN) PHARMACEUTICAL COMPOSITION USING LACTOBACILLUS SP. KCCM 11826P STRAIN FOR PREVENTING HYPERPHOSPHATEMIA AND FOR TREATING CHRONIC KIDNEY DISEASE AND HEALTH FUNCTIONAL FOOD
(FR) COMPOSITION PHARMACEUTIQUE UTILISANT LA SOUCHE LACTOBACILLUS SP. KCCM 11826P POUR PRÉVENIR L'HYPERPHOSPHATÉMIE ET POUR TRAITER LA MALADIE RÉNALE CHRONIQUE, ET ALICAMENT
(KO) 락토바실러스 SP. KCCM 11826P 균주를 이용한 고인산혈증 예방, 만성 신장질환 치료용 약학조성물 및 건강기능성 식품
要約: front page image
(EN) The present invention relates to a pharmaceutical composition for preventing or treating hyperphosphatemia and kidney disease and a health functional food for improving hyperphosphatemia and kidney disease by using a Lactobacillus sp. KCCM 11826P strain that is superior in terms of phosphorus absorption ability. Having excellent phosphorous absorption ability, the Lactobacillus sp. KCCM 11826P selected according to the present invention can greatly inhibit intestinal phosphorous absorption by the human body. In addition, the strain can be used as an alternative of a conventional calcium-based phosphate binder so as to minimize side effects attributed to an increase in blood calcium level, with the consequent effective prevention or treatment of hyperphosphatemia and kidney disease complications. Further, the Lactobacillus sp. KCCM 11826P selected according to the present invention can be provided for ingestion at lower cost compared to a conventional phosphate binder, and is far more convenient to ingest than a conventional phosphate binder since the strain can be developed into yogurt, powder, a nutritional food for patients, etc. in consideration of strain characteristics.
(FR) La présente invention concerne une composition pharmaceutique destinée à la prévention ou au traitement de l'hyperphosphatémie et de maladies rénales, et un alicament destiné à soulager l'hyperphosphatémie et la maladie rénale au moyen d'une souche Lactobacillus sp. KCCM 11826P ayant une capacité d'absorption du phosphore supérieure. Du fait de son excellente capacité d'absorption du phosphore, le Lactobacillus sp. KCCM 11826P choisi selon la présente invention peut fortement inhiber l'absorption intestinale du phosphore par le corps humain. En outre, la souche peut être utilisée comme alternative à un liant phosphate classique à base de calcium de manière à réduire au minimum les effets secondaires liés à une augmentation du taux de calcium dans le sang, assurant ainsi la prévention ou le traitement efficace de l'hyperphosphatémie et des complications des maladies rénales. En outre, le Lactobacillus sp. KCCM 11826P choisi selon la présente invention peut être fourni pour ingestion à moindre coût par rapport à un liant phosphate classique, et est beaucoup plus pratique à ingérer qu'un liant de phosphate classique puisque la souche peut être élaborée en yaourt, en poudre, en aliment nutritionnel pour des patients, etc. compte tenu des caractéristiques de la souche.
(KO) 본 발명은 인 흡수 능력이 뛰어난 락토바실러스 sp. (Lactobacillus sp.) KCCM 11826P 균주를 이용한 고인산혈증 신장질환 예방 또는 치료용 약학조성물 및 고인산혈증 신장질환 개선용 건강기능성 식품에 관한 것이다. 본 발명에 따르면, 본 발명에서 선별한 락토바실러스 sp. (Lactobacillus sp.) KCCM 11826P는 인 흡수 능력이 뛰어나 장내에서 인체 내로의 인 흡수를 우수하게 저해할 수 있다. 또한, 종래의 칼슘을 기반으로한 인 결합제를 대체할 수 있어, 혈중 칼슘 농도 증가로 인한 부작용을 최소화할 수 있고, 이로 인하여 고인산혈증 및 신장질환 합병증을 효과적으로 예방 또는 치료할 수 있다. 또한, 본 발명에서 선별한 락토바실러스 sp. KCCM 11826P는 기존의 인 결합제에 비하여 매우 저렴한 가격으로 복용이 가능하고, 균주의 특성상 요구르트, 분말 또는 환자의 영양식 등으로 개발이 가능하므로, 기존의 인 결합제보다 복용이 매우 편리하다.
指定国: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
アフリカ広域知的所有権機関(ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
ユーラシア特許庁(EAPO) (AM, AZ, BY, KG, KZ, RU, TJ, TM)
欧州特許庁(EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
アフリカ知的所有権機関(OAPI) (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
国際公開言語: 韓国語 (KO)
国際出願言語: 韓国語 (KO)